Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
Dolores Isla, Carme Sarries, Rafael Rosell et al. · Annals of Oncology · 2004
Cited by 294 works. doi:10.1093/annonc/mdh319
Authors
- Dolores Isla
- Carme Sarries
- Rafael Rosell
- G. Alonso
- Manuel Dómine
- Miquel Tarón
- Guillermo López-Vivanco
- Carlos Camps
- Mónica Botia
- L. Núñez
- M. Sánchez-Ronco
- José Javier Sánchez
- M. López-Brea
- I. Barneto
- Alfredo Paredes
- Begoña Medina
- Angel Artal
- PILAR LIANES
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
- Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans.
- Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
- Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter GeneABCB1
- ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
- ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy
- The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells
- Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
- Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.